Understanding insurance coverage for GLP-1 medications

Whether a GLP-1 medication is covered, and what you'll pay, comes down to a handful of specific plan rules. Once you know how each one works, a confusing denial turns into a set of concrete questions you can get answered.

The four things that decide your coverage

1. Formulary status and tier

The formulary is your plan's official list of covered drugs, sorted into cost tiers (generic, preferred brand, non-preferred brand, specialty). GLP-1 medications usually sit in the higher, more expensive tiers. Some formularies exclude them for weight management while covering the same drug for diabetes. Our guide on checking whether your formulary covers GLP-1 medications walks through how to check your plan and who decides what's on the list.

2. Prior authorization

Prior authorization (PA) means your prescriber has to send the insurer documentation of medical necessity before the plan will pay. For weight-management GLP-1s, that usually means showing a qualifying BMI (often 30 or higher, or 27 or higher with a weight-related condition) and sometimes a record of earlier weight-loss efforts. Cigna's policy for Foundayo, effective September 1, 2026, is a typical example: it asks for a BMI of at least 30, or at least 27 with a condition such as high blood pressure, plus at least 3 months of behavioral and dietary changes. How long a PA review takes varies by plan. It's a common place for a prescription to stall, often because documentation is missing or incomplete, not because anyone has said no.

3. Step therapy

Step therapy means you have to try one or more lower-cost alternatives, and have them fail or not suit you, before the plan will cover the medication you and your prescriber want. For GLP-1s, a plan might require a trial of another covered medication first. Your plan's PA criteria document spells out which steps apply.

4. The diagnosis: diabetes or weight management

The same molecule is often sold under different brand names for different uses: semaglutide is Ozempic for type 2 diabetes and Wegovy for weight management, and tirzepatide is Mounjaro for type 2 diabetes and Zepbound for weight management. Plans can treat those differently, covering the diabetes drug while excluding the weight-management one. If you have type 2 diabetes, the diabetes-indicated version may be covered under your plan's diabetes criteria, which require a documented type 2 diabetes diagnosis. Using Ozempic or Mounjaro for weight loss without type 2 diabetes is off-label use, so ask your plan how it handles that before you count on coverage.

How to check your own plan, step by step

1. Confirm the formulary status and tier for the exact drug and brand (see our formulary-checking guide).
2. Ask whether prior authorization or step therapy applies, and request the plan's PA criteria document if there is one. It tells your prescriber exactly what to document.
3. Confirm whether your plan covers the drug for your diagnosis (diabetes or weight management). This can differ even within the same insurer.
4. Ask about your copay, coinsurance, and where you stand against your deductible and out-of-pocket maximum. Those set your real cost even once a drug is "covered."
5. If you have employer-sponsored insurance, check with HR or benefits. Some self-funded employers exclude GLP-1 weight-management coverage regardless of the insurer's standard formulary. See our guide on talking to your employer about GLP-1 coverage.

What to do if you hit a wall

• If prior authorization is pending or unclear, ask your prescriber's office what documentation it submitted and whether anything is missing. A PA delay often means paperwork is missing, and nobody has actually said no yet.
• If you're denied, you have the right to appeal. See our FAQ: My insurance denied coverage. What now?
• If your plan requires a step you've effectively completed already (for example, you tried another approach before but it isn't well documented), ask your prescriber whether that history can be submitted to satisfy the requirement.
• If your plan covers the drug but the copay is steep, a manufacturer savings card can cut what commercially insured patients pay. See our side-by-side guide to GLP-1 savings cards.
• If your employer plan excludes the drug entirely, most copay cards won't apply, because they require coverage. Lilly's cards are the main exception: as of September 2026, commercially insured people whose plan doesn't cover Zepbound can pay as low as $299 for a 1-month KwikPen or vial fill with the Zepbound savings card ↗ (external link) (it expires 12/31/2026), and Mounjaro's card has a similar non-covered tier (details in our savings card guide). Otherwise your options shift to manufacturer direct-pay cash prices through LillyDirect or NovoCare Pharmacy (see how manufacturer direct-pay works), or to raising the exclusion with your employer's benefits team during open enrollment.

Coverage rules vary by plan, employer, and diagnosis, and they change often, sometimes every year as formularies are renegotiated. Confirm the specifics with your insurer and prescriber. This is general information, not medical or legal advice; for decisions about your treatment, talk with your care team.